Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1828]
News [2773]
Articles [208]
Editorials [1]
Conferences [136]
elearning [13]
Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer
Prof Jean Emmanuel Kurtz - Strasbourg Cancer Institute, Strasbourg, France
Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer ( Prof Jean Emmanuel Kurtz - Strasbourg Cancer Institute, Strasbourg, France )
10 Sep 2022
Topics under discussion at the WCLC 2022 presidential symposium
Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Topics under discussion at the WCLC 2022 presidential symposium ( Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
9 Aug 2022
Atezolizumab vs best supportive care in resected NSCLC
Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
Atezolizumab vs best supportive care in resected NSCLC ( Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )
9 Aug 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )
25 Jul 2022
Low-dose nivolumab leads to improved overall survival for head and neck cancer...
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Low-dose nivolumab leads to improved overall survival for head and neck cancer patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
19 Jul 2022
Updates from the PROpel and MAGNITUDE studies
Prof Phil Cornford and Dr Elena Castro
Updates from the PROpel and MAGNITUDE studies ( Prof Phil Cornford and Dr Elena Castro )
11 Jul 2022
Update on the latest in PARP inhibitors for prostate cancer
Prof Axel Merseburger and Prof Bertrand Tombal
Update on the latest in PARP inhibitors for prostate cancer ( Prof Axel Merseburger and Prof Bertrand Tombal )
11 Jul 2022
Isatuximab + Pd in Difficult-to-Treat Patients with RRMM
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Pd in Difficult-to-Treat Patients with RRMM ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
11 Jul 2022
ASCO Direct Highlights 2022: prostate cancer highlights
Dr Chandler Park - Baptist Health Hardin, Elizabethtown, USA
ASCO Direct Highlights 2022: prostate cancer highlights ( Dr Chandler Park - Baptist Health Hardin, Elizabethtown, USA )
9 Jul 2022
The advances in the management of patients with Hodgkin lymphoma and non...
Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute...
The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma ( Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA )
9 Jul 2022
Latest updates in hormone receptor positive HER2 negative breast cancer
Dr Mariana Chavez MacGregor - MD Anderson Cancer Center, Houston, USA
Latest updates in hormone receptor positive HER2 negative breast cancer ( Dr Mariana Chavez MacGregor - MD Anderson Cancer Center, Houston, USA )
8 Jul 2022
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
28 Jun 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation